Novartis International AG /
Novartis acquires all remaining rights to GSK''s Ofatumumab to develop treatments
for MS and other autoimmune indications
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
* Novarti ...
↧